mySHARED
Shared MHC-bound target discovery - Cohort-level shared antigen discovery
mySHARED applies dedicated cohort-level discovery pipelines to identify MHC-bound targets shared across defined cancer populations. Source-specific workflows generate candidate targets from SNVs, indels, and dark-genome antigens, including camyotopes. Our neoMS and neoIM algorithms then rank candidates by predicted presentation and immunogenicity before antigen sets are prioritized for broad population coverage.
What mySHARED delivers
Large-scale patient-cohort analyses have an average turnaround time of two to three months:
- Genome-wide association studies → linking genetic variation to phenotypes such as treatment response, disease progression, or therapeutic targets
- Differential expression and translation analysis
- Presentation prediction: identification of MHC-presented epitopes on both MHC class I and MHC class II molecules
- Immunogenicity prediction: identification of presented epitopes recognized by both CD4 and CD8 immune cells
- Coverage optimization: matching antigen targets with population of interest for optimal coverage
- Final epitope selection: based on antigen score, clonality, functional relevance, and immune-escape likelihood
- myCONSTRUCT: next-generation string-of-beads design (optional)
- myRNA: next-generation codon optimization (optional)
What is mySHARED?
mySHARED applies dedicated cohort-level discovery pipelines to identify MHC-bound targets shared across a defined cancer population. Source-specific workflows generate candidates from SNVs, indels, and dark-genome antigens, including camyotopes. neoMS and neoIM rank these candidates by predicted presentation and immunogenicity before antigen sets are prioritized for population coverage.
What is the typical turnaround for mySHARED?
Large-scale patient-cohort analyses with mySHARED have an average turnaround time of two to three months. Project timing depends on cohort scope and data readiness.